Fluconazole-, Amphotericin-B-, Caspofungin-, and Anidulafungin-Resistant Candida ciferrii: An Unknown Cause of Systemic Mycosis in a Child

Mycopathologia

Volumn 172, Issue 3, 2011, Pages 237-239

  Agın, Hasan ^a   Ayhan, Yüce ^a   Devrim, Ilker ^a   Gülfidan, Gamze ^a   Tulumoglu, Şener ^a   Kayserili, Ertan ^a  

^a Dr Behcet Uz Child Disease and Pediatric Surgery Training and Research Hospital   (Turkey)

Author keywords

Amphotericin B; Anidulafungin; Candida ciferri; Candidemia; Caspofungin; Fluconazole; Voriconazole

Indexed keywords

CANDIDA; STEPHANOASCUS CIFERRII;

EID: 79960604226     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-011-9418-6     Document Type: Article

References (15)

1. Kreger-van Rij NJ. Candida ciferrii, a new yeast species. Mycopathol Mycol Appl. 1965; 26: 49-52.
2. Gunsilius E, Lass-Flörl C, Kähler CM, et al. Candida ciferrii, a new fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients. Ann Hematol. 2001; 80: 178-9.
3. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nation wide study in Iceland. J Clin Microbiol. 2002; 40: 3489-92.
4. Takakura S, Fujihara N, Saito T, et al. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother. 2004; 53: 283-9.
5. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis. 1998; 31: 327-32.
6. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect. 2004; 10(Suppl 1): 11-23.
7. Tan TY, Tan AL, Tee NW, Ng LS. A retrospective analysis of antifungal susceptibilities of candida bloodstream isolates from Singapore hospitals. Ann Acad Med Singapore. 2008; 37(10): 835-40.
8. Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002. J Clin Microbiol. 2004; 42: 3142-6.
9. Furman RM, Ahearn DG. Candida ciferrii and Candida chiropterorum isolated from clinical specimens. J Clin Microbiol. 1983; 18(5): 1252-5.
10. de Gentile L, Bouchara JP, Le Clec'h C, Cimon B, Symoens F, Chabasse D. Prevalence of Candida ciferrii in elderly patients with trophic disorders of the legs. Mycopathologia. 1995; 131: 99-102.
11. Cheng MF, Yu KW, Tang RB, Fan YH, Yang YL, Hsieh KS, Ho M, Lo HJ. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis. 2004; 48: 33-7.
12. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007; 10(3): 121-30. Epub 2007 Jun 13.
13. Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother. 2007; 59(4): 767-71.
14. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009; 48(5): 503-35.
15. Morace G, Polonelli L, GISIA Group. Voriconazole activity against clinical yeast isolates: a multicentre Italian study. Int J Antimicrob Agents. 2005; 26(3): 247-53.